Citations

Clear

6273 citation(s) found for "To, Andrew".

Genetic overlap between endometriosis and endometrial cancer: evidence from cross‐disease genetic correlation and GWAS meta‐analyses
Painter, Jodie N. , O’Mara, Tracy A. , Morris, Andrew P. , Cheng, Timothy, Gorman, Maggie, Martin, Lynn , Hodson, Shirley, Henders, Anjali K. , McEvoy, Mark , Holliday, Elizabeth , Scott, Rodney J. , Webb, Penelope M. , Fasching, Peter A. , Beckmann, Matthias W. , Ekici, Arif B. , Hein, Alexander , Rübner, Matthias, Dörk, Thilo , Hillemanns, Peter , Runnebaum, Ingo B. , Lambrechts, Diether , Annibali, Daniela , Depreeuw, Jeroen, Goode, Ellen L. , Cunningham, Julie M. , Dowdy, Sean C. , Trovik, Jone , Høivik, Erling A. , Werner, Henrica M.J., Krakstad, Camilla , Ashton, Katie A. , Otton, Geoffrey, Proietto, Tony, Tham, Emma , Mints, Miriam, Healey, Catherine S., Shah, Mitul , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Hopper, John L. , Peto, Julian , Swerdlow, Anthony J. , Burwinkel, Barbara , Brenner, Hermann , Meindl, Alfons, Brauch, Hiltrud , Lindblom, Annika , Chang‐Claude, Jenny , Couch, Fergus J. , Kristensen, Vessela N. , Zondervan, Krina T. , Nyholt, Dale R. , MacGregor, Stuart , Tomlinson, Ian , Easton, Douglas F. , Thompson, Deborah J. , Lambrechts, Diether , Fasching, Peter A , Dörk, Thilo , Lambrechts, Diether , Goode, Ellen L , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Swerdlow, Anthony J , O'Mara, Tracy A , Lambrechts, Diether , Brenner, Hermann , Ekici, Arif B , Michailidou, Kyriaki , MacGregor, Stuart , Jones, Angela , Martin, Nicholas G. , Gordon, Scott D. , Attia, John , Hall, Per N , Czene, Kamila , Dürst, Matthias , Amant, Frédéric , Vanderstichele, Adriaan , Winham, Stacey J. , Mints, Miriam , Ahmed, Shahana , Pharoah, Paul D.P. , Dunning, Alison M. , Dennis, Joe , Tyrer, Jonathan P. , Meindl, Alfons, Couch, Fergus J. , Giles, Graham G. , Cox, Angela , Montgomery, Grant W. , Spurdle, Amanda B. , Brauch, Hiltrud , Lindblom, Annika

Mayo Clinic

Cancer Medicine | April 2, 2018 | Volume: 7 | Issue: 5 | Pages: 1978-1987

10.1002/cam4.1445 | PMID 29608257 Get It

AbstractEpidemiological, biological, and molecular data suggest links between endometriosis and endometrial cancer, with recent epidemiological studies providing evidence for an association between a previous diagnosis of endometriosis and risk of endometrial cancer. We used genetic data as an alternative approach to investigate shared biological etiology of these two diseases. Genetic correlation analysis of summary level statistics from genomewide association studies (GWAS) using LD Score regression revealed moderate but significant genetic correlation (rg = 0.23, P = 9.3 × 10−3), and SNP effect concordance analysis provided evidence for significant SNP pleiotropy (P = 6.0 × 10−3) and concordance in effect direction (P = 2.0 × 10−3) between the two diseases. Cross‐disease GWAS meta‐analysis highlighted 13 distinct loci associated at P ≤ 10−5 with both endometriosis and endometrial cancer, with one locus (SNP rs2475335) located within PTPRD associated at a genomewide significant level (P = 4.9 × 10−8, OR = 1.11, 95% CI = 1.07–1.15). PTPRD acts in the STAT3 pathway, which has been implicated in both endometriosis and endometrial cancer. This study demonstrates the value of cross‐disease genetic analysis to support epidemiological observations and to identify biological pathways of relevance to multiple diseases.
Developing drugs for treatment of atopic dermatitis in children (≥3 months to
Siegfried, Elaine C. , Jaworski, Jennifer C., Eichenfield, Lawrence F. , Altman, Emily , Arena, Charles, Block, Julie, Boguniewicz, Mark , Chen, Suephy C. , Hanna, Diane , Horii, Kimberly A., Hultsch, Thomas , Lio, Peter , Milner, Joshua D. , Omachi, Theodore A. , Schneider, Lynda C. , Sidbury, Robert , Smith, Timothy W. , Sugarman, Jeffrey, Taha, Sharif, Tofte, Susan, Tollefson, Megha M. , Tom, Wynnis L. , Whitney, Lucinda , Zane, Lee T., Tollefson, Megha, Paller, Amy S. , Hebert, Adelaide Ann , Simpson, Eric Lawrence , Blauvelt, Andrew , Cordoro, Kelly M. , Lee, James , Leung, Donald Y.M. , Schneider, Christine B. , Sugarman, Jeffrey, West, Dennis Paul

Mayo Clinic

Pediatric Dermatology | March 30, 2018 | Volume: 35 | Issue: 3 | Pages: 303-322

10.1111/pde.13452 | PMID 29600515 Get It

AbstractAtopic dermatitis is the most common chronic skin disease, and it primarily affects children. Although atopic dermatitis (AD) has the highest effect on burden of skin disease, no high‐level studies have defined optimal therapy for severe disease. Corticosteroids have been used to treat AD since the 1950s and remain the only systemic medication with Food and Drug Administration approval for this indication in children, despite published guidelines of care that recommend against this option. Several clinical trials with level 1 evidence have supported the use of topical treatments for mild to moderate atopic dermatitis in adults and children, but these trials have had little consistency in protocol design. Consensus recommendations will help standardize clinical development and trial design for children. The Food and Drug Administration issues guidance documents for industry as a source for “the Agency's current thinking on a particular subject.” Although they are nonbinding, industry considers these documents to be the standard for clinical development and trial design. Our consensus group is the first to specifically address clinical trial design in this population. We developed a draft guidance document for industry, Developing Drugs for Treatment of Atopic Dermatitis in Children (≥3 months to <18 years of age). This draft guidance has been submitted to the Food and Drug Administration based on a provision in the Federal Register (Good Guidance Practices).
Changes in International Normalized Ratios After Plasma Transfusion of Varying Doses in Unique Clinical Environments
Hanson, Andrew C. , Weister, Timothy J. , Higgins, Andrew , Madde, Nageswar R., Schroeder, Darrell R. , Kreuter, Justin D. , Kor, Daryl J. , Higgins, Andrew A, Schroeder, Darrell , Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | March 28, 2018 | Volume: 127 | Issue: 2 | Pages: 349-357

10.1213/ane.0000000000003336 | PMID 29596103 Get It

BACKGROUND: Plasma transfusion is commonly performed for the correction of abnormal coagulation screening tests. The goal of this investigation was to assess the relationship between the dose of plasma administered and changes in coagulation test results in a large and diverse cohort of patients with varying levels of coagulation abnormalities and comorbid disease and in a variety of clinical settings. METHODS: In this single-center historical cohort study, all plasma transfusion episodes in adult patients with abnormal coagulation screening tests were extracted between 2011 and 2015. The primary outcome was the proportion of patients attaining normal posttransfusion international normalized ratio (INR ≤ 1.1) with secondary outcomes including the proportion of patients attaining partial normalization of INR (INR ≤ 1.5) or at least 50% normalization in pretransfusion values with respect to an INR of 1.1. RESULTS: In total, 6779 unique patients received plasma with a median (quartiles) pretransfusion INR of 1.9 (1.6–2.5) and a median transfusion volume of 2 (2–3) units. The majority (85%) of transfusions occurred perioperatively, with 20% of transfusions administered prophylactically before a procedure. The median decrease in INR was 0.4 (0.2–0.8). Complete INR normalization was obtained in 12%. Reductions in INR were modest with pretransfusion INR values <3. Patients receiving ≥3 units of plasma were more likely to achieve at least 50% normalization in INR than those receiving ≤2 units (68% vs 60%; P < .001). CONCLUSIONS: Changes in INR after plasma transfusion were modest at typically used clinical doses, particularly in those with less severely deranged baseline coagulation screening tests. Further studies are necessary to assess the relationships between plasma-mediated changes in INR and clinical outcomes.
Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function
Barreto, Jason N. , McClanahan, Allison L., Thompson, Carrie A. , Frazee, Erin N. , Frazee, Erin N , Rule, Andrew D.

Mayo Clinic

Case Reports in Hematology | March 26, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-5

10.1155/2018/7169897 | PMID 29780646 Get It

High-dose methotrexate (MTX; ≥1 g/m2) is a renally eliminated and nephrotoxic first-line therapy for central nervous system (CNS) lymphoma. Creatinine-based estimation of renal function is the recommended approach to dosing MTX in these cases, but nonrenal determinants of creatinine production and elimination in cancer patients such as malnutrition and cachexia lead to overestimation of glomerular filtration rate (GFR) by this method and a heightened risk for drug toxicity. Serum cystatin C is one of the first readily available, relatively inexpensive, endogenous biomarkers to emerge as a practical adjunct to creatinine for estimation of renal function for drug dosing. In this report, we describe two cases where cystatin C was used in conjunction with creatinine to inform MTX dosing for CNS lymphoma. In both cases, the estimated GFR was nearly 40% lower with the combination of the two biomarkers compared to creatinine-only estimates. Empiric MTX dose reductions as a product of these results likely spared the patients sustained exposure to toxic drug concentrations and facilitated earlier administration of supportive care interventions. Further prospective investigations with validated dosing regimens including cystatin C are warranted for high-dose MTX.
Recurrent GNA 14 mutations in anastomosing haemangiomas
Bean, Gregory R. , Joseph, Nancy M. , Folpe, Andrew L. , Horvai, Andrew , Umetsu, Sarah E.

Mayo Clinic

Histopathology | March 25, 2018 | Volume: 73 | Issue: 2 | Pages: 354-357

10.1111/his.13519 | PMID 29574926 Get It

Networking Matters: A Social Network Analysis of the Association of Program Directors of Internal Medicine
Warm, Eric J. , Arora, Vineet M. , Chaudhry, Saima , Halvorsen, Andrew J. , Schauer, Daniel P. , Thomas, Kris G., McDonald, Furman S., Warm, Eric , Halvorsen, Andrew, Thomas, Kris

Mayo Clinic

Teaching and Learning in Medicine | March 22, 2018 | Volume: 30 | Issue: 4 | Pages: 415-422

10.1080/10401334.2018.1441715 | PMID 29565686 Get It

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD
Major-Monfried, Hannah , Renteria, Anne S. , Pawarode, Attaphol , Reddy, Pavan , Ayuk, Francis , Holler, Ernst , Efebera, Yvonne A. , Wölfl, Matthias , Wudhikarn, Kitsada , Ordemann, Rainer, Young, Rachel , Hartwell, Matthew J. , Chaudhry, Mohammed S., Aziz, Mina, Etra, Aaron , Yanik, Gregory A. , Kröger, Nicolaus , Weber, Daniela , Chen, Yi‐Bin , Nakamura, Ryotaro , Rösler, Wolf, Kitko, Carrie L. , Harris, Andrew C. , Kowalyk, Steven, Morales, George , Torres, I.M., Özbek, Umut , Ferrara, James L.M. , Levine, John E. , Kroger, Nicolaus , Kroger, Nicolaus , Levine, John E , Hogan, William J. , Qayed, Muna , Hexner, Elizabeth O. , Shah, Jay Narayan , Pulsipher, Michael A. , Reshef, Ran , Kröger, Nicolaus

Mayo Clinic

Blood | March 15, 2018 | Volume: 131 | Issue: 25 | Pages: 2846-2855

10.1182/blood-2018-01-822957 | PMID 29545329 Get It

Key Points Biomarker scores generated after 1 week of steroid treatment of GVHD are prognostic. Biomarkers reflect prognosis better than early clinical response to GVHD treatment.
Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States†
Khurmi, Narjeet , Chang, Yu‐Hui, Steidley, D. Eric , Singer, Andrew L., Hewitt, Winston R. , Reddy, Kunam , Moss, Adyr A. , Mathur, Amit K.

Mayo Clinic

Liver Transplantation | March 15, 2018 | Volume: 24 | Issue: 10 | Pages: 1398-1410

10.1002/lt.25055 | PMID 29544033 Get It

Cardiovascular disease (CVD) is a leading cause of post–liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology and outcomes of inpatient CVD care across US hospitals. Using a merged data set from the 2002‐2011 Nationwide Inpatient Sample and the American Hospital Association Annual Survey, we evaluated liver transplant patients admitted primarily with myocardial infarction (MI), stroke (cerebrovascular accident [CVA]), congestive heart failure (CHF), dysrhythmias, cardiac arrest (CA), or malignant hypertension. Patient‐level data include demographics, Charlson comorbidity index, and CVD diagnoses. Facility‐level variables included ownership status, payer‐mix, hospital resources, teaching status, and physician/nursing‐to‐bed ratios. We used generalized estimating equations to evaluate patient‐ and hospital‐level factors associated with mortality. There were 4763 hospitalizations that occurred in 153 facilities (transplant hospitals, n = 80). CVD hospitalizations increased overall by 115% over the decade (P < 0.01). CVA and MI declined over time (both P < 0.05), but CHF and dysrhythmia grew significantly (both P < 0.03); a total of 19% of hospitalizations were for multiple CVD diagnoses. Transplant hospitals had lower comorbidity patients (P < 0.001) and greater resource intensity including presence of cardiac intensive care unit, interventional radiology, operating rooms, teaching status, and nursing density (all P < 0.01). Transplant and nontransplant hospitals had similar unadjusted mortality (overall, 3.9%, P = 0.55; by diagnosis, all P > 0.07). Transplant hospitals had significantly longer overall length of stay, higher total costs, and more high‐cost hospitalizations (all P < 0.05). After risk adjustment, transplant hospitals were associated with higher mortality and high‐cost hospitalizations. In conclusion, CVD after liver transplant is evolving and responsible for growing rates of inpatient care. Transplant hospitals are associated with poor outcomes, even after risk adjustment for patient and hospital characteristics, which may be attributable to selective referral of certain patient phenotypes but could also be related to differences in quality of care. Further study is warranted.
Early Allograft Dysfunction Is Associated With Higher Risk of Renal Nonrecovery After Liver Transplantation
Wadei, Hani M. , Lee, David D. , Croome, Kristopher P. , Mai, Lorraine, Leonard, Deanne, Mai, Martin L., Taner, C. Burcin , Croome, Kris P , Lee, David D , Mai, Martin L., Keaveny, Andrew P. , Wadei, Hani M

Mayo Clinic

Transplantation Direct | March 15, 2018 | Volume: 4 | Issue: 4 | Pages: e352

10.1097/txd.0000000000000771 | PMID 29707623 Get It

Abstract Early allograft dysfunction (EAD) identifies allografts with marginal function soon after liver transplantation (LT) and is associated with poor LT outcomes. The impact of EAD on post-LT renal recovery, however, has not been studied. Data on 69 primary LT recipients (41 with and 28 without history of renal dysfunction) who received renal replacement therapy (RRT) for a median (range) of 9 (13-41) days before LT were retrospectively analyzed. Primary outcome was renal nonrecovery defined as RRT requirement 30 days from LT. Early allograft dysfunction developed in 21 (30%) patients, and 22 (32%) patients did not recover renal function. Early allograft dysfunction was more common in the renal nonrecovery group (50% vs 21%, P = 0.016). Multivariate logistic regression analysis demonstrated that EAD (odds ratio, 7.25; 95% confidence interval, 2.0-25.8; P = 0.002) and baseline serum creatinine (odds ratio, 3.37; 95% confidence interval, 1.4-8.1; P = 0.007) were independently associated with renal nonrecovery. History of renal dysfunction, duration of renal dysfunction, and duration of RRT were not related to renal recovery ( P > 0.2 for all). Patients who had EAD and renal nonrecovery had the worst 1-, 3-, and 5-year patient survival, whereas those without EAD and recovered renal function had the best outcomes ( P < 0.001). Post-LT EAD was independently associated with renal nonrecovery in LT recipients on RRT for a short duration before LT. Furthermore, EAD in the setting of renal nonrecovery resulted in the worst long-term survival. Measures to prevent EAD should be undertaken in LT recipients on RRT at time of LT.